How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

731 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. (PubMed)

Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. The Sibutramine Cardiovascular Outcomes (SCOUT) trial protocol defines a patient population predominantly outside current European Union label criteria. This article explores responses to sibutramine during the 6-week, single-blind, lead-in period between patients who conformed to the label requirements ("conformers") and those who did not ("nonconformers"). SCOUT (...) is an ongoing, randomized, double-blind, placebo-controlled outcome trial in overweight/obese patients at high risk of a cardiovascular event. In total, 10,742 patients received sibutramine and weight management during the lead-in period. Initial responses were assessed post hoc in label conformers and nonconformers. Of that 8.1% patients met label criteria; 91.9%, the majority with cardiovascular disease and/or blood pressure >145/90 mm Hg, were nonconformers. Conformers and nonconformers had similar

Full Text available with Trip Pro

2010 Obesity

42. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. (PubMed)

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Preclinical evidence suggests that pharmacotherapy for obesity using combinations of agents targeted at distinct regulatory pathways may produce robust additive or synergistic effects on weight loss. This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine. All (...) patients also received lifestyle intervention. Following a 1-week placebo lead-in, 244 obese or overweight, nondiabetic subjects (88% female; 41 +/- 11 years; BMI 37.7 +/- 5.4 kg/m(2); weight 103 +/- 19 kg; mean +/- s.d.) received placebo subcutaneously (sc) t.i.d., pramlintide sc (120 microg t.i.d.), pramlintide sc (120 microg t.i.d.) + oral sibutramine (10 mg q.a.m.), or pramlintide sc (120 microg t.i.d.) + oral phentermine (37.5 mg q.a.m.) for 24 weeks. Treatment was single-blind for subjects

Full Text available with Trip Pro

2010 Obesity

43. Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans. (PubMed)

Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans. Sibutramine is a centrally acting monoamine reuptake inhibitor prescribed as an appetite suppressant in the management of obesity. Its effects are mostly attributable to serotonin and norepinephrine transporter (SERT and NET, respectively) inhibition by its potent metabolites mono-desmethylsibutramine (M1) and di-desmethylsibutramine (M2). However, there is a paucity (...) of in vivo data in humans about mechanisms underlying both clinical efficacy and the dose-independent non-response observed in a minority of patients. Twelve healthy male patients (mean age 41 years) completed a double-blind, placebo-controlled, within-subject crossover investigation of brain SERT occupancy by sibutramine 15 mg daily at steady state. Correlations were measured between occupancy and (i) plasma concentrations of sibutramine, M1 and M2; (ii) appetite suppression. (11)C-DASB PET scans were

Full Text available with Trip Pro

2010 Neuropsychopharmacology

44. Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine. (PubMed)

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine. The aims of present study were 1) to evaluate cardiac valve characteristics, 2) to determine the plasma concentrations of fibrinogen, high sensitivity C-reactive protein (hsCRP), adiponectin, and tumor necrosis factor-alpha (TNF-alpha) in the obese women before and after 19 months sibutramine treatment in the obese women.Sixty obese women were enrolled in this prospective, randomized study. Thirty women (...) received 10 mg once daily dose of sibutramine for 19 months. The rest of the obese women received 15 mg once daily dose of sibutramine for 19 months. All patients were evaluated with echocardiography. Plasma levels of adiponectin and TNF-alpha were measured by enzyme-linked immunosorbent assay (ELISA) and hsCRP by immunoturbimetric assay. Student paired and unpaired t tests were used to compare the 10 mg or 15 mg dose sibutramine effects either in groups or between the groups.There were no signs

Full Text available with Trip Pro

2010 Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology

45. Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. (PubMed)

Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. We used functional magnetic resonance imaging to explore brain responses to food images in overweight humans, examining independently the impact of a prescan meal ("satiety") and the anti-obesity drug sibutramine, a serotonin and noradrenaline reuptake inhibitor. We identified significantly different responses (...) to these manipulations in amygdala, hypothalamus, and ventral striatum. Each region was specifically responsive to high-calorie compared to low-calorie food images. However, the ventral striatal response was attenuated by satiety (but unaffected by sibutramine), while the hypothalamic and amygdala responses were attenuated by drug but unaffected by satiety. Direct assessment of regional interactions confirmed the significance of this double dissociation. We explored the regional responses in greater detail

Full Text available with Trip Pro

2010 The Journal of neuroscience : the official journal of the Society for Neuroscience

46. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. (PubMed)

Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients.Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take (...) sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP), body weight, body mass index (BMI), glycated hemoglobin (HbA(₁c)), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein

2010 Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques

47. Sibutramine: suspension of EU licences recommended

Sibutramine: suspension of EU licences recommended Sibutramine: suspension of EU licences recommended - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Sibutramine: suspension of EU licences recommended Evidence indicates risks outweigh benefits. Published 11 December 2014 From: Therapeutic area: Article date: February 2010 The European Medicines Agency (EMA) has completed a review of the obesity medicine sibutramine (Reductil) on the basis of new safety information from a large (...) clinical trial, the Sibutramine Cardiovascular OUTcomes (SCOUT) study. The review has found that the cardiovascular risks of sibutramine outweigh its benefits. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended suspension of the licences for this medicine across the European Union. SCOUT was a randomised, double-blind, placebo controlled study in approximately 10 000 obese and overweight patients with cardiovascular disease and/or type 2 diabetes treated over a 6-year

2010 MHRA Drug Safety Update

48. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. (PubMed)

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Previous meta-analyses investigating blood pressure effects of anti-obesity drugs have included studies using non-licensed doses, but not data from head-to-head studies. Furthermore, although diabetes is an important comorbidity in obesity, variation in blood pressure effects across diabetes status has not been investigated. The objective of this study was to estimate the effects on systolic (SBP (...) ) and diastolic blood pressure (DBP) of orlistat and sibutramine. Medline, EMBASE, the Cochrane controlled trials register and reference lists of identified articles from 1990 to February 2009 were searched. All placebo-controlled randomized controlled trials of 12-month duration or randomized head-to-head studies of any duration on adults using standard doses were included. Studies/study arms were excluded if they only evaluated weight maintenance after weight loss. Randomized controlled trials were

2010 Obesity reviews : an official journal of the International Association for the Study of Obesity

49. No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. (PubMed)

No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. The health and longevity effects of body weight reduction resulting from exercise and caloric restriction in rodents are well known, but less is known about whether similar effects occur with weight reduction from the use of a pharmaceutical agent such as sibutramine, a serotonin-norepinephrine reuptake inhibitor.Using data from a 2-year toxicology study of sibutramine

Full Text available with Trip Pro

2010 International Journal of Obesity

50. WITHDRAWN: Interventions for treating obesity in children. (PubMed)

, orlistat and sibutramine) were found in 10 studies. No surgical intervention was eligible for inclusion. The studies included varied greatly in intervention design, outcome measurements and methodological quality.Meta-analyses indicated a reduction in overweight at 6 and 12 months follow up in: i) lifestyle interventions involving children; and ii) lifestyle interventions in adolescents with or without the addition of orlistat or sibutramine. A range of adverse effects was noted in drug RCTs.While (...) there is limited quality data to recommend one treatment program to be favoured over another, this review shows that combined behavioural lifestyle interventions compared to standard care or self-help can produce a significant and clinically meaningful reduction in overweight in children and adolescents. In obese adolescents, consideration should be given to the use of either orlistat or sibutramine, as an adjunct to lifestyle interventions, although this approach needs to be carefully weighed up against

Full Text available with Trip Pro

2019 Cochrane

54. Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00941382 Recruitment Status : Unknown Verified July 2009 by Laboratorios Silanes S.A. de C.V.. Recruitment status

2009 Clinical Trials

55. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). (PubMed)

Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). To explore vital sign changes among patient subgroups during the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.SCOUT is an ongoing, double-blind, randomized, placebo-controlled outcome trial in overweight/obese patients at high risk of a cardiovascular event. During the 6-week lead (...) -in period, 10,742 patients received sibutramine and weight management. Vital sign changes were assessed post hoc by initial blood pressure (mmHg) categorized as normal (<130/<85), high-normal (130 to <140/85 to <90) or hypertensive (>or=140/>or=90); weight change categories (weight gain/no weight change, >0 to 2.5% weight loss, >2.5 to 5% weight loss and >5% weight loss) and current antihypertensive medication class use (none, one, or two or more). To assess the impact of sibutramine on blood pressure

2009 obesity & metabolism

56. Long-term effects of weight-reducing drugs in people with hypertension. (PubMed)

heterogeneity was present, we used the random-effects method and investigated the cause of heterogeneity.After updating the literature search, which was extended to include four new weight-reducing drugs, we identified one additional study of phentermine/topiramate, bringing the total number of studies to nine that compare orlistat, sibutramine, or phentermine/topiramate to placebo and thus fulfil our inclusion criteria. We identified no relevant studies investigating rimonabant, liraglutide, lorcaserin (...) , or naltrexone/bupropion. No study included mortality and cardiovascular morbidity as predefined outcomes. Incidence of gastrointestinal side effects was consistently higher in those participants treated with orlistat versus those treated with placebo. The most frequent side effects were dry mouth, constipation, and headache with sibutramine, and dry mouth and paresthaesia with phentermine/topiramate. In participants assigned to orlistat, sibutramine, or phentermine/topiramate body weight was reduced more

2016 Cochrane

57. Is there any evidence to support the use of sibutramine as an antidepressant?

Is there any evidence to support the use of sibutramine as an antidepressant? Is there any evidence to support the use of sibutramine as an antidepressant? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence to support the use of sibutramine as an antidepressant? In 2001 NHS Tayside published a prescribing review of sibutramine [1], reporting: “Sibutramine is a new anti-obesity agent, which at first glance seems

2008 TRIP Answers

58. Can sibutramine and orlistat be combined in severe cases of obesity?

Can sibutramine and orlistat be combined in severe cases of obesity? Can sibutramine and orlistat be combined in severe cases of obesity? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Can sibutramine and orlistat be combined in severe cases of obesity? The CKS guideline on obesity considers the combination of sibutramine and orlistat and states: " There is evidence from one study to suggest that the addition of orlistat to sibutramine does

2008 TRIP Answers

59. Assessing and managing children at primary health-care facilities to prevent overweight and obesity in the context of the double burden of malnutrition

adolescents. Pharmacotherapy: most studies were small and of short duration, the notable exceptions being two large RCTs of sibutramine and orlistat. Sibutramine led to a mean estimated change in BMI from baseline of –3.1 kg/m 2 versus –0.3 kg/m 2 for placebo over 12 months. Orlistat was also beneficial, with a mean change in BMI of –0.55 kg/m 2 versus a change of +0.31 kg/m 2 in the placebo group at 12 months. Bariatric surgery: most papers presented clinical observations and there were no RCTs. Robust

2017 World Health Organisation Guidelines

60. Obesity in Adolescents

agents in the management of obesity in adolescents. Medical therapies are most often employed for adolescents who have not responded to lifestyle changes or for those with medical comorbidities. Only tetrahydrolipstatin is approved by the U.S. Food and Drug Administration for use in adolescents and it is considered the first-line adjunct to behavioral interventions ( ). Sibutramine was voluntarily withdrawn from the market in 2010 because of cardiovascular concerns (82). Tetrahydrolipstatin

2017 American College of Obstetricians and Gynecologists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>